PXL770 is a novel orally bioavailable, small-molecule direct AMPK activator with EC50 of 16.2, 42.1 and 64 nM for α1β1γ1, α1β1γ2 and α1β1γ3, directly increases AMPK activity by both allosteric activation and protection from dephosphorylation.
PXL770 monohydrate potassium salt is a novel orally bioavailable, small-molecule direct AMPK activator with EC50 of 16.2, 42.1 and 64 nM for α1β1γ1, α1β1γ2 and α1β1γ3, directly increases AMPK activity by both allosteric activation and protection from dephosphorylation.
PXL770 improves glucose metabolism and dyslipidemia in rodent models of metabolic syndrome, and reduces hepatic DNL in vitro and in vivo.
PXL770 ameliorated each of the classical NASH hallmarks, including steatosis, ballooning, inflammation, and fibrogenesis in diet‐induced (DIO) mouse NASH model.
